Abstracts Archive - Page 624 of 2607 - ACR Meeting Abstracts

Abstract Number: 2116 • ACR Convergence 2022
Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
Juan Josè de Agustin¹, Gustavo Añez¹, delia reina², Sergi Heredia³, Felipe Julio Ramirez Garcia⁴, Andrea Cuervo⁵, Jesus Rodriguez⁶, Carmen Moragues⁶, Patricia Moya⁷, Mireia Moreno⁸, Marta Arévalo⁸, Manel Pujol⁹, Georgina Salvador⁹, Noemi Busquets¹⁰, andres Ponce¹⁰, Ana Maria Laiz Alonso⁷ and MAria Pascual Pastor¹¹, ¹Vall D'hebron University Hospital, Barcelona, Spain, ²Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, ³Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, ⁴Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, ⁶Hospital Bellvitge, Hospitalet de Llobregat, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, ⁹Hospital Universitario MútuaTerrassa, Terrassa, Spain, ¹⁰Hospital General de Granollers, Granollers, Spain, ¹¹Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Christopher Ritchlin¹, Philip J Mease², Wolf-Henning Boehncke³, John Tesser⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, May Shawi⁷, Elena Schiopu⁸, Joseph Merola⁹, Iain B McInnes¹⁰ and Atul Deodhar¹¹, ¹Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁰Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
Abstract Number: 2123 • ACR Convergence 2022
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Jesus Diaz¹, Guillermo Quiceno² and Adela Castro³, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
Abstract Number: 2125 • ACR Convergence 2022
Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
Joseph Merola¹, Iain B McInnes², Arthur Kavanaugh³, Peter Nash⁴, Zhenyi Xue⁵, Vassilis Stakias⁶, Ann Eldred⁷, Sandra Ciecinski⁸, Kevin Douglas⁶ and Laura Coates⁹, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴School of Medicine, Griffith University, Sunshine Coast, Australia, ⁵AbbVie, Inc., Wilmington, DE, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Lake Bluff, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.Methods: KEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus…
Abstract Number: 2122 • ACR Convergence 2022
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna Gladman¹, Lars Erik², Diamant Thaci³, Paolo Gisondi⁴, Laure Gossec⁵, M. Elaine Husni⁶, Alice Gottlieb⁷, Hiroaki Dobashi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and William Tillett¹², ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ³Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ⁴Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁵Sorbonne Université, Paris, France, ⁶Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
Abstract Number: 2124 • ACR Convergence 2022
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
Stefan Siebert¹, Laura Coates², Georg Schett³, Siba P. Raychaudhuri⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷, Frederic Lavie⁸, Elke Theander⁹, Marlies Neuhold¹⁰, Alexa Kollmeier¹¹, Xie L Xu¹², Proton Rahman¹³, Philip J Mease¹⁴ and Atul Deodhar¹⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ⁹Janssen Cilag, Lund, Sweden, ¹⁰Janssen, Zug, Switzerland, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹³Memorial University, St. John's, NL, Canada, ¹⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹⁵Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate…
Abstract Number: 2135 • ACR Convergence 2022
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
James C Waddington¹, Ruoyi Zhou¹, Orla Coleman¹, Bruna Wundervald², Andrew Parnell³, Vinod Chandran⁴, Lara Fallon⁵, Douglass Chapman⁶, Remy Pollock⁷, Shibing Deng⁸, Oliver FitzGerald⁹, Stephen R Pennington¹⁰ and Philip J Mease¹¹, ¹Atturos, Dublin, Ireland, ²Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, ³Hamilton Institute, Maynooth University, Kildare, Ireland, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Canada ULC, Kirkland QC, Canada, ⁸Pfizer Inc, Waterford, MI, ⁹Conway Institute, University College Dublin, Dublin, Ireland, ¹⁰Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 2070 • ACR Convergence 2022
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
Sarah Dyball¹, John Reynolds², Hector Chinoy³, Ariane Herrick¹, Sahena Haque⁴, Ellen Bruce⁵, Sophia Naz⁶, Ben Parker⁷ and Ian N. Bruce⁸, ¹The University of Manchester, Manchester, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³The University of Manchester, Sale, United Kingdom, ⁴Manchester Foundation Trust, Manchester, United Kingdom, ⁵Kellgren Centre for Rheumatology, Manchester, United Kingdom, ⁶Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ⁷Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁸Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…
Abstract Number: 2127 • ACR Convergence 2022
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Laura Coates¹, Laure Gossec², Christine Contré³, May Shawi⁴, Emmanouil Rampakakis⁵, Natalie Shiff⁶, Alexa Kollmeier⁷, Xie L Xu⁸, Peter Nash⁹, Philip J Mease¹⁰ and Philip Helliwell¹¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Sorbonne Université, Paris, France, ³Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁴Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁷Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁸Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…
Abstract Number: 2136 • ACR Convergence 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
Arthur Kavanaugh¹, Laura Coates², Joseph Merola³, Philip J Mease⁴, Miroslawa Nowak⁵, Subhashis Banerjee⁵, Lauren Hippeli⁵ and Tom Lehman⁵, ¹University of California San Diego, La Jolla, CA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 2140 • ACR Convergence 2022
Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
Philip J Mease¹, Dafna Gladman², Georg Schett³, Maria Paris⁴, Sue Cheng⁵, Sven Richter⁵, Lichen Teng⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Amgen Inc., Westfield, NJ, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶University of California San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…
Abstract Number: 2130 • ACR Convergence 2022
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
Petros P. Sfikakis¹, Dimitrios Vassilopoulos², Gkikas Katsifis³, Georgios Vosvotekas⁴, Theodoros Dimitroulas⁵, Argyro Repa⁶, Grigorios Sakellariou⁷, THEODORA SIMOPOULOU⁸, Athanasios Georgountzos⁹, Andreas Bounas¹⁰, Panagiotis Georgiou¹¹, Evangelia Mole¹², Evangelia Kataxaki¹³, Stamatis Nick Liossis¹⁴, Evangelos Theodorou¹⁵, Christina Antoniadou¹⁶, EVANGELOS THEOTIKOS¹⁷, PANAYIOTIS VLACHOYIANNOPOULOS¹⁸, THEODORA MARKATSELI¹⁹, Angeliki Kekki²⁰, NIKOLAOS ANTONAKOPOULOS²¹ and Dimitrios Boumpas²², ¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ³Naval Hospital of Athens, Athens, Greece, ⁴Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁵4th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁶Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, ⁷Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, ⁸Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, ⁹General Hospital of Athens G. Gennimatas, Athens, Greece, ¹⁰Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, ¹¹Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, ¹²Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, ¹³Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, ¹⁴Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, ¹⁵Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, ¹⁶First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ¹⁷Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, ¹⁸Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²⁰Genesis Pharma SA, Halandri, Greece, ²¹Genesis Pharma SA, Chalandri, Greece, ²²4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…
Abstract Number: 1810 • ACR Convergence 2022
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
Tuhina Neogi¹, Martin Englund², Aleksandra Turkiewicz² and Ali Kiadaliri², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Treatment guidelines for management of gout do not recommend opioids. We evaluated the frequency of opioid prescriptions in those with gout compared with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].